Synthesis of 2-Substituted 4-Arylidene-5(4H)-oxazolones as Potential Cytotoxic Agents in the Presence of Lemon Juice as a Biocatalyst

Author:

Prasad Malavattu G.1,Lakshmi Chapala V.1,Katari Naresh K.1,Anand Krishnan2,Pal Manojit3ORCID,Jonnalagadda Sreekantha B.4

Affiliation:

1. Department of Chemistry, School of Science, GITAM deemed to be University, Hyderabad 502 329, India

2. Discipline of Medical Biochemistry and Chemical Pathology, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

3. Dr. Reddy's Institute of Life Sciences, University of Hyderabad Campus, Hyderabad 500046, India

4. School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, P Bag X 54001, Durban 4000, South Africa

Abstract

Background: The oxazolone class of compounds is known to exert a profound effect on malignant cell proliferation, tumor angiogenesis and /or on the established neoplastic vasculature. Additionally, these compounds are generally known to have a low tendency to interact with DNA which is not common with most of the conventional cytotoxic agents. Thus, this class of compounds is of particular interest for the discovery and development of patient-friendly anticancer agents. Objective: The initial objective of this study was to synthesize and evaluate 2-substituted 4-arylidene- 5(4H)-oxazolones for their potential anticancer properties. Methods: A simple, mild and non-hazardous synthetic methodology has been developed for the preparation of 2-substituted 4-arylidene-5(4H)-oxazolones. The methodology involved lemon juice mediated condensation of N-acyl glycine derivatives including hippuric acid with arylaldehydes in PEG-400 under ultrasound irradiation. All the synthesized compounds were screened via an MTT assay for their potential cytotoxic properties in vitro using the cancerous cell lines e.g. K562 (human chronic myeloid leukemia), Colo-205 (human colon carcinoma), and A549 (human lung carcinoma) and a non-cancerous HEK293 (human embryonic kidney) cell line. Results: Compounds 3a, 3c and 3i showed promising growth inhibition against A549 cell line but no significant effects on HEK293 cell line, indicating their selectivity towards cancer cells. Moreover, their IC50 values suggested that all these compounds were comparable to the reference drug doxorubicin indicating their potential against lung cancer. Conclusion: he 4-arylidene-5(4H)-oxazolone framework presented here could be a new template for the design and discovery of potential anticancer agents especially for lung cancer.

Publisher

Bentham Science Publishers Ltd.

Subject

Organic Chemistry,Computer Science Applications,Drug Discovery,General Medicine

Reference52 articles.

1. Erlenmeyer E.; Ueber die Condensation der Hippursäure mit Phtalsäureanhydrid und mit Benzaldehyd. Annalen 1893,275,1-8

2. Sharma N.; Banerjee J.; Shrestha N.; Chaudhury D.; A review on oxazolone, it’s method of synthesis and biological activity. Eur J Biomed Pharm Sci 2015,2,964-987

3. Argade N.D.; Kalrale B.K.; Gill C.H.; microwave assisted improved method for the synthesis of pyrazole containing 2,4,-disubstitutedoxazole-5-one and their antimicrobial activity. Eur J Chem 2008,5,120-129

4. Tandon M.; Coffen D.L.; Gallant P.; Keith D.; Ashwell M.A.; Potent and selective inhibitors of bacterial methionyl tRNA synthetase derived from an oxazolone-dipeptide scaffold. Bioorg Med Chem Lett 2004,14(8),1909-1911

5. Parveen M.; Ali A.; Ahmed S.; Malla A.M.; Alam M.; Pereira Silva P.S.; Silva M.R.; Lee D.U.; Synthesis, bioassay, crystal structure and ab initio studies of Erlenmeyer azlactones. Spectrochim Acta A Mol Biomol Spectrosc 2013,104,538-545

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3